Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It's early in the morning and the "fly in the ointment" is filling the air with mindless blather!
Remember: it's not what the fly "says", it's where he's been (Yuck!)
PATHETIC
....I'm the fly in the ointment......
Finally, self knowledge!
(but) Caution, you know where flies also like to hang-out (hint, dogs make a necessary contribution)
One more article with an astonishing negative spin, it's bizarre!
From the article:
The pigs have done their morning dump!
Very unedifying! Wish they would do it in private!
From the...[ whichever end ] of the "AutoEich999" combine:
Gnat!!
The "mixed result" nonsense seems to have blotted out simple commons sense! A medication with similar comfort levels and MUCH better efficacy, so that the primary goal, relief from DES symptoms is faster, seems to me to win at all around. The "mixed result" crowd doesn't understand the obvious, that faster relief is a measure of "comfort".
Silly article:
https://finance.yahoo.com/news/aurinia-pharmaceuticals-buy-193321889.html
Gnats and Gadflies offer zero value, we've known that from Ariad days!
The Leerink statement says it all:
Positive Ph.2a data demonstrated superiority
for voclosporin ophthalmic solution (VOS) over Restasis in key
efficacy endpoints for dry eye syndrome (DES), but no difference
in tolerability, given abnormally well tolerated Restasis experience
in this trial;
The "Mixed Result" headline is about the most astonishingly misleading nonsense, and that WAS obvious immediately. The "failure" is that both medications had very mild tolerability issues, BUT one drug (VOS) was massively superior in efficacy. "MIXED"??? LOL!
It's kind of hard to beat mild irritation with EVEN MILDER irritation! The GNAT thinks we're going to five, who knows, after all, the "market" is stupid, but if we do, it's time to add a few thousand shares.
Hi Allo, thanks for the link!
What is really interesting for me is the warm and enthusiastic embrace of our technology at the highest levels (Gottlieb!!! the model of what an enlightened, dedicated public servant should be!). It was not Pluristem specific, but it's a good indication of what knowledgeable people expect, and the position this segment of the biotech industry will occupy in the near future. Needless to say that I'm hoping that we will be a major player in that space.
So even if the administrative mechanisms they're putting in place may take a few months to be activated, the interest in cell/regen technologies is there NOW, and should be a factor in moving this technology to the clinic expeditiously.
...
(strategic elision of my thoughts about "AutoEich999")
As far as Pluristem (which is the reason I'm here!) I'm very excited about the coming months. The two recent presentations, where two physicians provided clinical evidence that different pathologies that cause terrible damage to the ability of blood vessels to perfuse tissues (Buerger's disease and Peripheral Arterial Diseases) can be dramatically reversed. What we have seen is patients in pain, watching their limbs develop gangrene, and facing imminent amputation and death, are brought back from the brink.
I do understand that two patients do not constitute a statistical sample, BUT, we have two top notch specialists, who believe that the reversal of the patient's devastating progression toward oblivion was halted by the intervention with Pluristem's PLX-PAD.
It's worth rereading Prof. Yoffe's statement (from recent article):
Following treatment with PLX-PAD cells, we observed demonstrable restoration of the patient’s peripheral blood supply to the injured limb, which was manifested by a significant improvement in color, warmth, wound size and reduced pain. One year following treatment, the wound is now fully closed, the patient was able to resume normal activities and amputation was prevented. This treatment highlights PLX-PAD’s ability to reduce inflammation, stimulate growth of new blood vessels and support treatment in ischemic conditions such as Buerger’s disease and Peripheral Arterial Diseases (PAD). Additionally, the other limb, which was in earlier stages of the disease, also showed signs of improvement demonstrating the cells’ ability to prevent progression of the disease and act as a potential systemic treatment. I am highly encouraged by these results providing hope for Buerger’s disease patients and am happy to see the significant improvement in the patient’s medical condition, quality of life and overall wellbeing.”
Dr. Lantis using PLX-PAD for a patient with CLI made similarly enthusiastic statements. These are serious, sober medical scientists, with huge clinical experience. They did not think the patient's healing was coincidence. We're accumulating solid evidence and it's been all positive so far. There's a lot here to be optimistic about!